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Abstract 
Introduction: Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are two 
common, heterogeneous, long-term illnesses which cause significant morbidity and mortality. 
Although they both present with breathlessness, they are treated differently. Treatment of 
COPD focuses mainly on relieving short-term breathlessness, whilst treatment of HF has 
focused on long term morbidity and mortality. 
Areas covered: In this review, we aim to highlight the diagnostic challenges in distinguishing 
COPD from HF. We also explore the implications of their overlap, and the use of biomarkers 
and treatments for HF in patients with COPD to improve long-term outcomes.  
Expert commentary: Cardiovascular morbidity and mortality amongst patients with COPD is 
substantial. Approaches which identify patients with COPD at highest cardiovascular risk 
may therefore be helpful. A trial targeting those patients with COPD and raised natriuretic 
peptide levels might be the way to test whether cardiovascular medication has anything to 
offer the respiratory patient. 
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1. Introduction 
The diagnosis of both heart failure (HF) and chronic obstructive pulmonary disease (COPD) 
is primarily clinical, based on a constellation of symptoms (mainly breathlessness during 
exercise and fatigue) and signs (such as peripheral oedema or raised jugular venous pressure) 
due to an underlying structural or functional abnormality.  Distinguishing between COPD and 
HF can be difficult, but is important. Active treatment of chronic heart failure, when it is due 
to a substantial reduction in left ventricular ejection fraction (HeFREF), can approximately 
double a patient’s life expectancy (1). However, despite a large number of trials, with 
thousands of patients enrolled, and enormous financial investment, there is very little 
evidence that treatment modifies the clinical course and mortality of either COPD or heart 
failure with normal ejection fraction (HeFNEF), despite some beneficial effects on symptoms 
(2,3). 
 
In this review, we examine the prevalence of COPD in patients with HF and vice versa. We 
discuss the diagnostic challenges in distinguishing COPD from HF, suggesting that clinicians 
should be aware of significant overlap when assessing patients with either condition. We also 
explore the implications of the overlap and the possible value of using biomarkers of HF as 
well as using treatment of HF in patients with COPD to improve long term adverse treatment 
outcomes.  
 
2. Distinguishing between HF and COPD 
Exertional breathlessness is the most common presentation to a heart failure clinic. By the 
time patients are seen in clinic, many will have a normally contracting left ventricle on 
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echocardiography with a slight increase in circulating levels of natriuretic peptides, and 
commonly, mild abnormalities on spirometry (4). A substantial proportion either smoked or 
continues to smoke, many are overweight and hypertensive, and very many are elderly and 
treated with a cocktail of drugs, including diuretics and inhalers (4, 5). Exertional 
breathlessness often persists despite treatment, and attempts to clarify the medical diagnosis 
further are a daily item of discussion: has that patient got COPD, or HF? Is either disease 
present, or perhaps neither? Does the patient need follow-up, further tests, or it is appropriate 
to discharge him/her back to the primary care physician?  
 
3. Epidemiology of COPD in patients with HF, and vice versa 
COPD and HF share predisposing risk factors, particularly a long history of smoking and 
systemic inflammation, and often coexist. The reported prevalence of COPD in patients with 
HF varies between 10% to 50 % (6) and is higher in patients with HF who have HeFNEF, 
rather than HeFREF, which perhaps reflects different patient characteristics in the two 
conditions. Patients with HeFNEF tend to be older, are more likely to be female and to have 
co-morbidities. Indeed, many patients with so-called HeFNEF are misdiagnosed and many 
are in fact breathless due to COPD (7).  
 
Patients with COPD have an increased risk of developing HF (8), and COPD increases 
morbidity and mortality in those who already have HF, with a greater burden in patients with 
HeFNEF, compared with those with HeFREF (9).  The prevalence of HF amongst patients 
with COPD is around 10-20%, although some studies report that the prevalence might be as 
high as 50% (10-12). The discrepancy suggests that a high proportion of patients enrolled in 
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COPD registries might have undiagnosed HF (13), and it might partially explain why a 
substantial proportion of patients with COPD are not only treated with diuretics but also die 
of cardiovascular causes rather than from progressive respiratory disease (14-18).  
Cardiovascular events are one of the major, if not the most common, reasons for hospital 
admissions in patients with COPD (19). An autopsy study found that nearly 60% of patients 
dying following an admission with severe COPD die of heart failure (37%) or pulmonary 
thromboembolism (21%), another 28% die from pneumonia, but fewer than 15% die from 
progression of underlying COPD (20). A dedicated clinical endpoint committee adjudicated 
the cause of death and the relationship of deaths to COPD of patients with enrolled in the 
TORCH (Towards a Revolution in COPD Health) study. Of the 911 deaths, the proportions 
attributed to COPD and to cardiovascular disease were similar (27%), and most of those 
attributed to cardiovascular causes were sudden (21). Subsequent reports confirmed that 
patients with COPD seem to be at an increased risk of sudden cardiac death, particularly 
when they have frequent exacerbations (14). There is some evidence that these dramatic 
cardiac events are more likely to be due to asystole or pulseless electric activity, rather than 
to ventricular tachyarrhrhythmias (22). Thus, the cardiovascular morbidity and mortality is 
substantial for patients with COPD, and might be modifiable by effective diagnosis and 
treatment. 
 
4. Heart failure as a mimic of COPD 
Triggered and perpetuated by chronic inflammatory responses to external pathogens 
(particularly smoking and air pollution), COPD is characterised by progressive narrowing of 
the small airways, and obliteration of the lung parenchymal tissue. The result is diminished 
elasticity of alveolar walls on expiration, with consequent breathlessness and fatigue 
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secondary to the strenuous respiratory effort made by the patients to keep the alveoli open 
(23, 24). A ratio of forced expiratory volume in the first second (FEV1) to forced vital 
capacity (FVC) of less than 70% is the diagnostic threshold for COPD (25). 
 
Patients with HF can appear to have obstructive or restrictive respiratory pathology on 
spirometry similar to that observed in patients with COPD, leading to diagnostic uncertainty. 
More than 30 years ago, Light and colleagues observed substantial impairment in FEV1 and 
FVC, characteristically seen in an obstructive and restrictive lung disease, amongst 28 
patients admitted with acute heart failure who were shown subsequently not to have COPD 
(26). The spirometric abnormalities improved once congestion was relieved. It seems that 
alveolar and interstitial oedema might compress airways and produce a picture similar to that 
observed in patients with COPD. More recently, Brenner and colleagues performed serial 
spirometry in patients admitted with HeFREF, and showed that apparent “COPD” resolved 
by 6 months in around 50% of patients once they were treated with appropriate anti-HF 
medication (27).  
 
A post-hoc analysis conducted in 187 patients with both HF and COPD enrolled in the 
CHAMPION trial (Cardiomems Heart Sensor Allows Monitoring of Pressure to Improve 
Outcomes in NYHA Class III Heart Failure Subjects) showed that optimising anti HF 
treatment and being more aggressive with diuretics in patients with invasively monitored 
increasing pulmonary artery pressure not only decreased the rate of hospitalisations for 
HF, but also for respiratory disease (28). It is possible that lowering pulmonary artery 
pressure with more appropriate anti HF medications causes lower rates of respiratory 
infections or COPD exacerbations. 
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Impaired lung functional tests are also seen in ambulatory patients with chronic HF who have 
no previous diagnosis of COPD:  around 25% of patients with chronic HF have FEV1 <80% 
predicted, and the proportion doubles in those with more severe HF symptoms. There is thus 
a huge potential for misdiagnosis, leading to unnecessary prescriptions of therapies targeting 
the “obstructed” airways (29). Impaired lung mechanics and reduced gas diffusion are other 
factors that could be partially responsible of a “COPD-like” picture in patients with chronic 
heart failure (30, 31).  Cardiomegaly and pleural or pericardial effusions can limit intra-
thoracic space and consequently further reduce lung function and volumes (32). Furthermore, 
respiratory muscle strength is reduced in patients with HF, causing dyspnoea and exercise 
limitation (33).  Other co-existing conditions, such as abdominal obesity, might also reduce 
lung volumes and function, causing symptoms erroneously attributed to COPD or HF (34). 
Anaemia and myocardial ischemia are other frequent comorbidities in patients with HF that 
might contribute to, and aggravate, breathlessness (35).   
 
5. A common diagnostic dilemma 
An imaging test demonstrating a poorly contracting left ventricle is often sufficient to 
establish the initial diagnosis of HeFREF (and to define the course of treatment) in a patient 
with shortness of breath; however, it is not so simple to make a straightforward diagnosis in 
patients whose left ventricle contracts relatively well (36). The prevalence of HeFNEF is 
reported to be on the rise, but its diagnosis remains challenging (37, 38). Several guidelines 
and consensus statements suggest that the presence of cardiac structural abnormalities or 
diastolic dysfunction on echocardiography is a requirement for the diagnosis of HeFNEF (1, 
39), but not all patients with breathlessness and diastolic dysfunction on imaging have 
HeFNEF (40). Diastolic dysfunction is very commonly seen in older people or in patients 
with hypertension, who do not necessarily report breathing difficulties or have peripheral 
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oedema (41).  Moreover, the presence of diastolic dysfunction on echocardiography does not 
always identify patients with a poorer outcome, particularly when natriuretic peptides are low 
(7, 42).  
 
Natriuretic peptides are hormones produced by the heart. Levels rise in response to pressure 
or fluid overload, and result in natriuresis and vasodilation. When their plasma concentrations 
rise in a patient with heart failure, there is a marked increase in the risk of adverse outcome, 
regardless of left ventricular ejection fraction (43, 44). The updated ESC-HF guidelines 
suggest that an NTproBNP below 125 ng/l excludes heart failure (1). An NTproBNP level 
>125 ng/l, accompanied by structural heart alterations (for example, a dilated left atrium) or 
diastolic dysfunction, implies the diagnosis of HeFNEF in a patient with symptoms 
suggestive of heart failure (1). Screening using natriuretic peptides in ambulatory patients 
with COPD might be a strategy to confirm, or refute, the diagnosis of HF and to identify 
those at greater risk of adverse outcome (table 1); such a strategy differentiates well between 
patients with lung and heart problems amongst those who present acutely with shortness of 
breath (45,46).   
 
The difficulties experienced by cardiologists in diagnosing heart failure are encountered in a 
similar manner by respiratory physicians when they attempt to separate normal from 
abnormal lung function tests. There is no equivalent of natriuretic peptides to help in the 
diagnosis of COPD. Adult smokers commonly have respiratory symptoms which limit their 
physical activity. They also have a substantial number of exacerbations requiring antibiotics 
and/or steroids, and evidence of chronic bronchitis on computed tomography (CT) scans even 
when spirometry is normal (FEV1/FVC>70), suggesting that spirometry may not be an 
adequate screening tool for COPD (47, 48).  As a consequence of their symptoms, many 
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patients with normal spirometry are treated with inhaled bronchodilator therapy despite not 
fulfilling clear diagnostic criteria for COPD. Such treatment might have a deleterious impact 
on any underlying heart disease, as we will discuss later.  
 
In the elderly, a decline in FEV1/FVC ratio <0.70 can be a physiological finding not related 
to obstructive lung disease, and other measurements have been proposed with the aim of 
avoiding over-diagnosing (and again, over-treating) COPD (49, 50). However, impaired lung 
function tests in an elderly individual are not necessarily a benign finding (51), particularly 
with worse spirometry and particularly when NTproBNP is increased. In a study of 3242 men 
drawn from the general population, without prior myocardial infarction or HF, and aged 60–
79 years, around 30% had FEV1/FVC<0.7. Those with a poorer predicted % FEV1 had more 
biochemical evidence of inflammation (raised C-reactive protein (CRP)) and cardiac damage 
(raised troponin I and NTproBNP) than those with a normal FEV1. The presence of 
moderate, or severe (FEV1/FVC <0.70 and FEV1 <80%)  airflow obstruction was associated 
with a high risk of developing HF, and % predicted FEV1 was an independent predictor of 
incident HF even in models corrected for NTproBNP (52). Decreasing FEV1 was one of the 
strongest predictors of incident HF in a study of around 6000 individuals older than 65 years, 
with and without known ischemic heart disease. (53).  
 
Right ventricular dysfunction and raised pulmonary artery pressure, as frequently occur in 
patients with COPD, are common clinical findings shared by patients with COPD and HF and 
might contribute to an increase in NTproBNP (and other plasma biomarkers) even in those 
with no left ventricular systolic dysfunction (54-57). It is not surprising that raised pulmonary 
artery pressure, and NTproBNP levels, carry powerful prognostic information in both 
populations (58,59).  
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6. Issues associated with treating heart failure in patients with COPD 
Beta-blockers are currently prescribed to around 90% of patients with HeFREF. The 
commonest reason not to prescribe a beta-blocker is the concomitant presence of respiratory 
disease (60, 61). The concern is that beta-blockers might have deleterious effects on lung 
function, such as bronchoconstriction, and might increase the airway responsiveness of 
patients with COPD (62).  
 
Despite their beneficial effect on left ventricular size and function, and on long term outcome, 
in patients with HeFREF (63), beta-blockers can decrease FEV1 and worsen airway 
resistance. The tolerability (defined as reaching, and maintaining, guideline-recommended 
target doses after 12 weeks treatment) of two widely used beta-blockers (carvedilol and 
bisoprolol) was assessed 883 elderly patients with HF in the Cardiac Insufficiency Bisoprolol 
Study in Elderly (CIBIS-ELD). Patients were naïve to, or not taking an adequate dose of, 
beta-blocker. Only 7% of the patients enrolled had a previous diagnosis of COPD; 31% of 
patients reached target doses of treatment with beta-blockers, and there was no difference in 
the tolerability of the two beta-blockers. Both beta-blockers improved clinical endpoints such 
as LVEF, and 6 minute walk test distance (+19 m for bisoprolol and + 13 m for carvedilol) 
after 12 weeks of treatment, but they had a differential effect on FEV1: FEV1 was unchanged 
by the cardioselective bisoprolol but significantly worsened in those treated with the non-
selective carvedilol. There was a greater number of pulmonary adverse events with carvedilol 
than bisoprolol, although the number of events was modest (44 (10%) vs 16 (4%), 
respectively, p=0.01) (64). 
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In patients with HF and co-existing moderate or severe COPD, bisoprolol, but not placebo, 
caused a substantial decrease in FEV1 (–70 mL from baseline vs +120 mL in the placebo 
group, p=0.01) but without significantly affecting symptoms or quality of life (65).  
 
In a cross-over trial in 51 patients with HF (mean LVEF 37%) of whom 35% had COPD, the 
respiratory, haemodynamic and biochemical effects of three licensed beta-blockers for 
patients with HF (metoprolol, carvedilol and bisoprolol) were evaluated. Compared to 
metoprolol and bisoprolol, carvedilol not only decreased FEV1, but also plasma NTproBNP, 
suggesting that it might have a more beneficial effect on the underlying heart failure. There 
were no major differences between the beta blockers in six-minute walk test (66).  
 
Despite the frequently given advice to avoid β blockers in people with COPD, cohort meta-
analyses suggest that patients with COPD but no clinically apparent heart disease might have 
a better prognosis when they are prescribed beta-blockers, and might have a lower risk of 
experiencing a COPD exacerbation; this is probably because many of them had had a 
diagnosis of underlying cardiovascular disease, including ischemic heart disease or heart 
failure, the likely reason for which a beta-blocker was originally prescribed (67-69). 
Similarly, large studies suggest that the use of other widely used anti-HF medications (such 
as ACE-inhibitors, or angiotensin II receptor blockers) in patients with COPD is associated 
with lower mortality, perhaps reflecting better diagnosis and treatment of relevant 
comorbidities (70, 71). 
 
7. Issues associated with treating COPD in patients with heart failure 
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Various treatments prescribed for COPD, alone or in combination, acutely improve lung 
function and symptoms, and might also have beneficial effect on cardiac haemodynamics 
(such as increasing the cardiac index, or lowering the end-diastolic ventricular pressure, 
and/or peripheral resistance) in patients with HF (72, 73).  The long term prescription of 
treatments for COPD has never been convincingly shown to reduce mortality (74-76). Worse, 
some of these treatments might even be harmful for patients with COPD, particularly in those 
with underlying heart disease. Au and colleagues reported that, amongst 1529 patients with 
HeFREF, the use of inhaled beta-agonists was associated with an increased risk of HF 
hospitalizations or death, with a dose-response relation (77, 78).  Some bronchodilatators 
increase the risk of all-cause mortality and cardiovascular death in patients with respiratory 
disease (79). Anticholinergic drugs, in particular tiotropium (80, 81), have recently been 
associated with an increased risk of death, due to possible pro-ischaemic and pro-arrhythmic 
effects (82, 83). The chronic and indiscriminate use of inhaled steroids further exposes 
patients to the risk of pneumonia or incident (or worsening) diabetes (84). Identifying 
patients in whom discontinuation of unnecessary COPD therapy is safe has to be 
encouraged (85).  
 
8. Expert commentary 
Heart failure and COPD have many things in common. They share a similar clinical 
presentation and an increasing prevalence (86, 87). They also share a poor prognosis, and a 
high social and economic burden.  
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As is the case for heart failure, COPD is a heterogeneous disease, and different phenotypes of 
patient have just started to be identified: they might have different characteristics and 
outcome, not all of which might necessarily benefit from similar treatment strategies.  
 
One example is that it is popularly thought that COPD progresses as a consequence of a rapid 
decline in FEV1. However, a substantial proportion of patients have COPD with a reduction 
in FEV1, but their FEV1 then declines at an approximately normal age-related rate. Such 
patients have a decreased FEV1 in their early adulthood (88), perhaps as a consequence of an 
exposure to one or another environmental factor, or because of some genetic predisposition. 
A therapeutic approach targeted at preventing rapid decline in FEV1 would be inappropriate 
for such patients. 
 
Moreover, other different subsets of individuals with COPD might exist. Those who have 
more cardiovascular comorbidities and evidence of inflammation have the highest mortality 
(usually cardiovascular); whilst those with lowest FEV1 and severe emphysema are at 
greatest risk of exacerbations and COPD admissions. In contrast, those with only mild 
symptoms have a low risk of exacerbations, and a 3 year mortality rate of only 3% (89). 
 
The wider use of biomarkers, such as natriuretic peptides, has enabled cardiologists to 
identify individuals with HF at low or high risk of adverse outcome, which may help in 
targeting specific treatments (7, 90), such as mineralcorticoid receptor antagonists (MRA). 
Currently, raised levels of NTproBNP are a mandatory criterion for enrolment in trials in 
HeFNEF. It may be that natriuretic peptides could be used to identify patients with COPD at 
greatest cardiovascular risk, likely to benefit from treatments targeted at heart disease (91).  
As with diabetes, where treatment that reduces cardiovascular risk, rather than treatment 
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aimed at reducing blood sugar, improves prognosis (92, 93), targeting cardiovascular risk in 
patients with COPD (rather than targeting lung function) might have a similar effect.  
 
An example might be the use of statin in COPD. However, although several large 
observational studies have suggested that statins might have beneficial effects in patients with 
COPD (70, 71), the STATCOPE trial of simvastatin in 885 patients with COPD without overt 
cardiovascular disease or diabetes was stopped for futility after a median follow up of 641 
days (94).  Another multicentre trial investigating the effect of metoprolol on the incidence of 
acute exacerbations in patients with moderate-severe COPD is ongoing (95).  
 
Markers of systemic inflammation, such as fibrinogen, might further provide insight into 
COPD pathophysiology and suggest other therapeutic options in other subsets of patients 
(96). Biomarkers might also be a useful tool to describe the heterogeneity of COPD 
exacerbations, which might be due to different pathogens, with different inflammatory 
responses, that might be prevented, or treated, in different ways (97).   
 
 
9. Five-year view 
Whilst trials in heart failure have focused on the effects of treatments on the rate of 
hospitalisations, and importantly, mortality, trials in COPD trials have mainly assessed the 
effects of interventions on quality of life and symptomatic relief.  Closer collaboration 
between cardiologists and lung specialists might be helpful as the diseases overlap and are 
sometimes not easily distinguishable; sharing the experience gained by cardiologists in recent 
decades might help improve trial design for patients who have COPD, either alone or with 
concomitant, and often undiagnosed, HF. 
   
14 
 
 
 
10. Conclusions 
COPD and HF are heterogeneous, and frequently overlapping, diseases. The development of 
pharmacotherapy for COPD has been intense, but has been mainly limited to compounds 
targeting airways obstruction, with no evidence of a mortality benefit, in contrast to the 
results of many trials in patients with HF. Death amongst patients with COPD is most 
commonly from cardiovascular causes, and thus approaches which identify patients with 
COPD at highest cardiovascular risk may be helpful. A trial targeting those patients with 
COPD and raised natriuretic peptide levels might be the way to test whether cardiovascular 
medication (beta-blockers, ACE-inhibitors or MRA) has anything to offer the respiratory 
physician. 
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Key issues 
 Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are two 
common and heterogeneous diseases that share a similar clinical presentation and 
might coexist; distinguish between the two is essential.  
 Identifying and treating patients with heart failure and reduced left ventricular 
ejection fraction (HeFREF) substantially prolongs patient’s life expectancy, whilst 
there is very little evidence that treatment modifies the clinical course and mortality of 
either COPD or heart failure with normal ejection fraction (HeFNEF). 
 As in heart failure, and many other clinical conditions, raised natriuretic peptides 
identify patients with COPD at higher cardiovascular morbidity and mortality risk.  
 Trials targeting cardiovascular risk in patients with COPD might be the way to test 
whether cardiovascular medication improves the long term outcome of these patients. 
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 Natriuretic peptides plasma levels Outcome 
Inoue (98) 60, without known 
cancer, cardiac or 
renal medical 
history. 
GOLD criteria Mean BNP: 41.0+6.6 pg/ml (vs 14.8+2.7 pg/ml in 
controls). BNP plasma levels increased with increasing 
COPD severity.  
 
BNP correlated with non-invasive 
estimation of pulmonary artery systolic 
pressure and LVEF. 
Only two patients died during 3 year 
follow-up. 
Kanat (91) 37 with a COPD 
exacerbation 
without evidence of 
cor pulmonale or 
heart failure; 15 
controls with stable 
COPD. 
 GOLD criteria BNP was elevated in 30 patients with acute COPD 
(81%). Patients with elevated BNP were randomised to 
mild diuretic (triamterene 50 mg + hydrochlorothiazide 
25 mg/day) vs no diuretic. 
Median BNP: 
Randomised to mild diuretic: 742 (283-3228) pg/ml 
Randomised to no-diuretic: 405 (184-2108) pg/ml 
Controls: 101 (63-342) pg/ml  
Adding mild diuretic to standard 
treatment of COPD rapidly reduces BNP 
levels.  
Van Gestel (99) 261 with LVEF>40% 
undergoing major 
vascular surgery 
(AAA, CEA or LLR).  
 
144 had COPD. 
GOLD criteria 73% of those with elevated NTproBNP (defined as >500 
pg/ml) had COPD, whilst only 52% of those with not 
elevated NTproBNP had COPD. 
Median NTproBNP: 
125 pg/ml no COPD 
212 pg/ml mild COPD 
170 pg/ml moderate COPD 
352 pg/ml severe COPD 
23 patients during 1 year follow-up.  
 
NTproBNP was independent predictor 
of mortality in all patients as well as in 
those with COPD. 
 
The 1 year survival rate in patients with 
COPD and NTproBNP<500 pg/ml was 
88% vs 65% in those > 500 pg/ml 
(<0.01). 
Leuchte (100) 176 with various 
pulmonary disease 
(of whom 45 had 
COPD) undergoing 
RHC. 
An impaired lung 
function test 
supported by 
radiographic and 
immunologic or 
histopathologic 
findings (depending 
on the disease).  
Mean BNP was 297 (54) pg/ml in patients with mean 
PAP>35 mmHg vs 26 (4) in those with mean PAP<35 
mmHg. 
BNP and mean PAP>35 mmHg were the 
strongest predictors of mortality.  
Waschki (101) 170 with COPD 
without clinical signs 
of HF.   
GOLD criteria Median NTproBNP was higher in nonsurvivors (98 (49-
209)pg/ml vs 64 (38-106) pg/ml, p=0.038 
NTproBNP was not an independent 
predictor of mortality.   
Stamm (102) 796 smokers 
without IHD, HF or 
CKD. 
GOLD criteria Median NTproBNP was 49 (22-94) pg/ml.  
Median NTproBNP in nonsurvivors was 71 (36-107) 
pg/ml vs 47 (21-93) in survivors. 
An NTproBNP above the median was an 
independent predictor of mortality 
(HR = 2.19, 95% CI 1.07–4.46, p = 0.031).  
Wannamethee 
(52) 
3242 men without 
MI or HF 
GOLD criteria. 
 
Data presented in 5 
groups, based on 
predicted FEV1. 
NTproBNP (median, pg/ml): 
<5th percentile of predicted FEV1: 116 (55-257) 
6-24th: 109 (49-220) 
25-49th: 87 (44-160) 
50-74th:78 (38-147) 
>75th: 81 (41-146) 
Reduced FEV1 and moderate or severe 
(FEV1/FVC <0.70 and FEV1 <80%) 
airflow obstruction was independently 
associated with incident HF.  
 
Associations between FEV1 and incident 
HF remained after adjustment for 
NTproBNP and cTNT. 
 
Table 1. Summary of studies investigating the potential role of natriuretic peptides in patients with pulmonary diseases. Abbreviations used: AAA - 
abdominal aortic surgery;  CEA - carotid endarterectomy ; LLR - lower limb arterial reconstruction; GOLD - Global Initiative for Chronic Obstructive Lung 
Disease; BNP - B-type natriuretic peptide; NTproBNP -  N-terminal prohormone of brain natriuretic peptide; LVEF - left ventricular ejection fraction; FU - 
follow up; COPD - chronic obstructive pulmonary disease; RHC - right heart catheterization;  PAP - pulmonary artery pressure; MI - myocardial infarction; 
IHD - ischaemic heart disease; HF - heart failure; CKD - chronic kidney disease; FEV1 - forced expiratory volume in one second; cTNT - cardiac troponin T; HR 
- hazard ratio; CI - confidence interval.  
